He brings up a great point that the Fed Chief should shut her trap. So if the Fed Chair is going to call sectors Over Valued...will she also call some under valued?...NEVER I have never heard a Fed Chair call a Wall Street sector UNDER VALUED. I tell you her comment was her trying to show that she is in touch with wallstreet...one of her flunky assistants (...who shorted some biotechs?) advised her on these sectors. SHE DOSEN'T HAVE A CLUE OTHERWISE. She is no Alan Greenspan.
Oh forgot one special case...people on high dose blood thinners who seem to have excessive bruising might be a special case. Also anyone with a bleeding disorder might benefit too. You probably can think of a few more.
The "special cases " patients who can't inject themselves. eg, Elderly patients who have little help at home. Patients with poor vision/blind. But not nursing home patient where there is always a nurse to give an injection. Patients with recurrent MRSA skin abcess. But not those who "don't like needles", a drug insurance is not going to approve an expensive drug for that. They will want to see a valid diagnosis of Needle Phobia in the chart after an evaluation by a Mental Health provider. So various protocols will screen out a lot of potential users. Now there is always the folks who have money who will demand it and pay out of pocket.
New Diabetes drug...ah no. its not new - its Insulin. And not even a new way of using it, I believe PFE had an inhaled Insulin product that FAILED. MNKD will have a difficulty time trying to get to market, for sure they need a partner ( unlike ACAD doesn't really need a partner). MNKD needs CASH and has a ton of DEBT. Watch out for the CEO to sell new shares....Their product supposedly might be used in 10% of the Diabetic population...but I seriously doubt it. perhaps 1-3% ( special cases ) . There are just too many generic products and really great alternatives like those Insulin Injector Pens-very tiny needles that you hardly feel, no refrigeration required and High Brand loyalty. Patients LOVE their Pens. Not to mention the BLACK BOX WARNING. But the value they have is in their new technology. Now if they can get it to work with other drugs...well that would really help the stock. Trading op....if they get a partner it will pop the stock...but I believe many will sell the High and get out fast. BTW. go look at the headlines on MNKD...some Hedge Fund guy is predicting MNKD will fall by 90%. So in general, it may be a big risk to buy & hold.
When you see a Biotech putting out a lot of "news" that really isn't news...like enrollment numbers....its time to take caution. Too much so-called "news " is usually done by Biotechs to boost their stock price. Its Fluff. Run like heck.
Did he make this #$%$ up or is this a well known and used term?
it could be just a pull back for the next POP and not a full fib at this point. Keep in mind there are bag holders from when this stock was over $100. So they want their money back at some point.
Yes they really don't need a partner, but say a partner with an existing production line and world wide sales force with a great record came into the picture, the contract would have to be very economical for ACAD to sign it.
I am not worried or concerned one tad. ACAD really doesn't need a partner, they have a TON of CASH = 369 Million and NO DEBT. And could easily raise 150-200 MILLION more to go it alone. A Buy Out is gonna cost say...MRK about 5 Billion ( thats BILLION with a B ). So they will not enter into a deal without major DD. They might be waiting for the Alzheimer's data or after an accepted NDA
Type Value Conf.
resist. 30.10 2
resist. 28.78 2
resist. 25.34 3
resist. 24.88 2
resist. 23.75 5
resist. 22.44 3
resist. 21.24 9
supp 20.09 9
supp 19.24 3
supp 17.88 4
Look at the chart for the max time...you will see a TON of holders who bought at a way higher price than the present price. They want out. So anytime this stock hits a higher level it will get SOLD OFF FAST.
Yep smart. Especially considering there are a TON of BAG HOLDERS from the past that want to get their money back. They will sell it off when it pops like today.
The first time I read this it just looked like a hit piece, but where are the 5 patient results. Did they drop out for personal reasons, eg, did they move out of the area? Especially the 4 treated - If they were removed from the study WHY. If later you find out one or several had died or some other unknown issue then it could sink the stock, lead to a Black Box Warning or worse? Where are the results? I for one feel this concern is valid.
..." But Inovio's per-protocol analysis of the study's primary endpoint omits patients. How many patient are missing from the analysis? We don't know because Inovio didn't disclose. The study was designed to enroll 148 patients, according to a design schema on ClinicalTrials.gov, but Inovio could have enrolled more. If 148 patients were enrolled, Inovio's per protocol analysis omits five patients -- four treated with VGX-3100 and one patient on placebo.
Inovio did not disclose the more important intent-to-treat analysis of the study's primary endpoint. "
Found this article...OUCH!!! Inovio CEO Preps Retail Investors for Drug Study Failure
By: Adam Feuerstein
Inovio Pharmaceuticals (INO) CEO Joseph Kim is walking back expectations for the phase II study of its DNA vaccine VGX-3100 in women with high-grade cervical intraepithelial neoplasia (CIN 2/3), also known as cervical pre-cancerous lesions. Results from the VGX-3100 study should be announced any day, but I suspect Inovio already has data in hand. Why else would Kim be laying the foundation for a massive spin job, if not to cushion the vaccine's failure?
The red flags flying over Inovio are there for any clear-eyed investor to see:
Inovio pushed through shareholder vote approving a 1-for-4 reverse stock split on May 23, which went into effect on June 5. Why the need for a reverse stock split? Kim explained:
Our stockholders approved a reverse split to have our price and share structure reflect our leadership position in immunotherapies and expand our potential investor audience.
Interesting spin. Drug companies in leadership positions aren't generally valued with stock prices in the $2 range. More typically, terminally depressed stock prices -- like Inovio's -- are the direct result of management incompetence and/or drug development setbacks and failures. Innovio is very good at issuing press releases and promoting its stock to retail investors, but its track record of developing DNA vaccines is abysmal.